Behavioral health company LifeStance Health (NASDAQ: LFST) will be announcing earnings results this Thursday morning. Here’s what investors should know.

LifeStance Health Group beat analysts’ revenue expectations last quarter, reporting revenues of $435.4 million, up 26.1% year on year. It was a stunning quarter for the company, with a beat of analysts’ EPS estimates and EBITDA guidance for next quarter exceeding analysts’ expectations.

Is LifeStance Health Group a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting LifeStance Health Group’s revenue to grow 18.7% year on year, improving from the 16.3% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. LifeStance Health Group has missed Wall Street’s revenue estimates multiple times over the last two years.

Looking at LifeStance Health Group’s peers in the healthcare providers & services segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Encompass Health delivered year-on-year revenue growth of 8.9%, beating analysts’ expectations by 0.5%, and DaVita reported revenues up 4.6%, topping estimates by 1.7%. Encompass Health traded up 7.7% following the results while DaVita was down 3%.

Read our full analysis of Encompass Health’s results here and DaVita’s results here.

There has been positive sentiment among investors in the healthcare providers & services segment, with share prices up 2.8% on average over the last month. LifeStance Health Group is up 11.6% during the same time and is heading into earnings with an average analyst price target of $14.45 (compared to the current share price of $13.64).

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.